Sino Biopharmaceutical Limited has announced the completion of patient enrollment in the Phase III registrational clinical trial of tecotabart vedotin (LM-302), an antibody-drug conjugate $(ADC)$ targeting CLDN18.2, for the treatment of third-line and later CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma. LM-302 is the world’s first CLDN18.2 ADC to reach this stage in a registrational trial. The latest results from a study evaluating LM-302 in combination with toripalimab for the treatment of gastric cancer were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12018666), on February 08, 2026, and is solely responsible for the information contained therein.